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Abstract
Background: Human follicular fluid (FF) is a unique biological fluid in which the oocyte develops in vivo, and
presents an optimal source for non-invasive biochemical predictors. Oocyte quality directly influences the embryo
development and hence, may be used as a predictor of embryo quality. Peptide profiling of FF and its potential
use as a biomarker for oocyte quality has never been reported.
Methods: This study screened FF for peptide biomarkers that predict the outcome of in vitro fertilization (IVF).
Potential biomarkers were discovered by investigating 2 training datasets, consisting both of 17 samples and
validating on an independent experiment containing 32 samples. Peptide profiles were acquired by nano-scale
liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS).
Results: From the training datasets 53 peptides were found as potential biomarker candidates, predicting
the fertilization outcome of 24 out of the 32 validation samples blindly (81.3% sensitivity, 68.8% specificity,
AUC = 0.86). Seven potential biomarker peptides were identified. They were derived from: insulin-like growth
factor binding protein-5, alpha-2-antiplasmin, complement component 3, inter-alpha-trypsin inhibitor heavy
chain H1, serum albumin, protein diaphanous homolog 1 and plastin-3.
Conclusions: The MS-based comprehensive peptidomic approach carried out in this study, established a
novel panel of potential biomarkers that present a promising predictive accuracy rate in fertilization outcome,
and indicates FF as an interesting biomarker resource to improve IVF clinic routine.
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Background
Over the years, in vitro fertilization is associated with a
high rate of multiple pregnancies, which presents both
perinatal complications and economic complaints [1–3].
To reduce the incidence of multiple pregnancies, single
embryo transfer (SET) is the only strategy [4, 5]. The
selection of high quality embryos remains the major
challenge in human assisted reproductive technology
(ART). Worldwide, the selection of embryos has been
based on morphological assessments. However, there
is still a lack of evidence-based standard for ranking
embryos and determining the embryo with the highest
implantation potential [6]. The low rate of successful
pregnancies creates the need to increase the predic-
tive value for implantation.
Given the fact that RNA, proteins, and cellular machi-
nery are provided by the oocyte during early zygote deve-
lopment, oocyte quality determines a big part of the
embryo development and hence, may be used as a
predictor of embryo quality [7]. Human follicular fluid
(FF) has been attracting researchers’ interest since it
is non-invasive and easily available. FF is a product of
both the transfer of blood plasma constituents that
cross the blood follicular barrier and of the secretory
activity of granulosa and thecal cells [8]. FF is a complex
mixture of proteins, metabolites, and ionic compounds,
which have been found to reflect the stage of oocyte deve-
lopment and the degree of follicle maturation [9–14].
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It has also been previously shown that altered FF compos-
ition is associated with a diminished reproductive capacity
[14, 15]. Therefore, it is reasonable to think that some
biochemical characteristics of the FF reflect oocyte quality
and influence fertilization [16]. In body fluids, biomarkers
are often low molecular weight peptides and proteins
[17, 18]. Given the complexity of the numerous indepen-
dent processes involved in oocyte maturation, it is unlikely
that a single biomarker can classify the oocytes [19].
Application of powerful proteomic and peptidomic tech-
nologies in reproductive medical research may significantly
contribute to help diagnosis but also the comprehensive
understanding of reproductive processes. Several laborato-
ries have demonstrated the feasibility of selecting peptide/
protein diagnostic biomarkers in follicular fluid [20–22].
Efforts to explore the follicular fluid proteomic sig-
nature using different proteomic approaches have been
carried out by several groups [19, 23–26]. The study per-
formed by Spitzer et al. compared protein patterns in FF
from immature and mature FF using two-dimensional gel
electrophoresis (2-DE) [27], reporting considerable diffe-
rences in protein patterns derived from fluids of immature
compared with matured follicles. Hanrieder et al. coupled
isoelectric focusing to nano liquid chromatography
and MALDI TOF/TOF, and identified 69 proteins in
FF of women undergoing IVF [28]. Twigt et al. using
SDS-PAGE and isoelectric focusing followed by LC-MS/
MS identified 246 FF proteins which are involved in
acute phase response and immunological function [19].
Ambekar et al. combined three different methods of
protein/peptide fractionation and identified 480 proteins
in FF [24]. A more recent study performed by Zamah et
al. identified 742 proteins in follicular fluid from fertile
woman [22].
Despite decades of efforts, comparative studies on
FF with respect to IVF outcome have not yet been
done yet. Specific and sensitive proteomic biomarker
candidates for IVF outcome have not been found. The low-
molecular-weight (LMW) subset of proteome is termed the
“peptidome”, including peptides and small proteins with
molecular weights generally less than 10,000. At the early
stage in the development of the peptidome field, the infor-
mation content of peptides resides in two general catego-
ries: first, bioactive peptides and fragments shed from cells
in the microenvironment, such as hormones and cytokines.
Therefore, peptides may reflect the cell-to-cell communica-
tions taking place in the microenvironment [29]. The other
is the cleavage products produced by enzymes and pro-
teases as a consequence of certain physiological or patho-
logical processes, such as apoptosis or necrosis, which may
serve as reporters for biological enzymatic states of individ-
uals [29–31]. Taking the diagnostic information carried by
the peptidome into consideration, measuring panels of
peptidome makers is expected to generate a higher
level of prognostic capacity. Peptides are constantly
generated in vivo by active synthesis, and by proteolytic
processing of larger precursor proteins, often yielding
protein fragments that mediate a variety of physio-
logical functions [32]. This study aimed to reveal if
peptide profiling of individual FF could become a new
non-invasive predictive biomarker for oocyte quality,
and attempted to discover candidate biomarkers for
fertilization. In biomarker studies, candidate biomarkers
need to be validated across a large number of samples
because of normal clinical or biological variability. To
ensure that the discovered biomarkers are truly associated
with fertilization three experiments were designed with a
relatively large population. We investigated the peptide pro-
file of human follicular fluid with successful fertilization
and unsuccessful fertilization from patients undergoing in
vitro fertilization using LC_MS/MS. We additionally
determined the protein identities of the discovered peptide
biomarkers as a first step toward understanding the
pathways in which they may function.
Methods
Study design
A total number of 66 follicular fluid samples from 50
couples undergoing IVF/ICSI treatment at the Leuven
University Fertility Center were analyzed. All the patients
were undergoing the first or second treatment cycle with
a single embryo transferred (SET) and ranged from 18 to
36 years old. Patients with repeated implantation failures
(cycle rank > 2) were not considered. Patients were fully
informed and consents were obtained before oocyte
retrieval. The study was approved by the Commission
for Medical Ethics of the University Hospital Leuven
(code ML6214).
The follicular fluid samples were analyzed in 3 expe-
riments. The first training dataset contained 17 samples
(8 successfully fertilized oocytes (showing 2 pronuclei),
9 unfertilized mature oocytes), the second training dataset
contained 17 samples (7 successfully fertilized oocytes,
10 unfertilized mature oocytes). The validation dataset
contained 32 samples (16 successfully fertilized oocytes,
16 unfertilized mature oocytes). All the fertilized oocytes
in this study resulted in implantation after SET. Samples
were randomly selected regardless the treatment of insem-
ination (IVF/ICSI). Samples of training sets and validation
sets were shown in Table 1. Patients’ characteristics were
detailed in Table 2 and Additional file 1: Table S2.
Ovarian stimulation, oocyte retrieval and follicular fluid
collection
The stimulation protocol used in this study has been
published by Debrock [33]. Briefly, ovarian stimulation
was carried out with gonadotropins (Menopur, Ferring,
Copenhagen, Denmark; Gonal-F or Metrodin HP, Merck-
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Serono, Geneva, Switzerland; Puregon, Organon, Oss,
The Netherlands) and GnRH agonists (Buserlin acetate,
Suprefact; Hoechst, Frankfurt, Germany) during a long or
short protocol. The follicular response was monitored
serum oestradiol levels and transvaginal ultrasound mea-
surements. The hCG, 10,000 IU, was administered when
at least three follicles reached a diameter of 17 mm.
Oocyte retrieval was performed 35 h after hCG injection
by ultrasound guided transvaginal aspiration. The luteal
phase was supported with intravaginal application of P
(600 mg/day, Utrogestan; Besins, Drogenbos, Belgium)
started at the evening of the hCG injection.
Follicular fluid was aspirated and collected separately,
then kept on ice immediately. Each follicle was flushed
twice. To maintain a stable pH in a room atmosphere
condition, commercial medium Dulbecco’s phosphate-
buffered saline (DPBS; Gibco, Paisley, UK) was used as
flushing medium. For each FF sample, the volume and
color appearance (yellow, light reddish, reddish, dark
reddish and red) were recorded. Only FF of yellow or
light reddish was allowed for further analysis.
The samples were centrifuged at 1500 * g for 10 min.
The supernatant was transferred to a cryotube and
stored in liquid nitrogen until further processing.
In vitro insemination/Intracytoplasmic sperm injection
Prior to fertilization, oocytes were washed 4 times
with wash medium GM501 (GM 501 Wash, Gynemed
Lensahn, Germany) after retrieval in order to minimize
the amount of blood/follicular fluid. Oocytes were placed
separately in a 4-well dish (Nunc, Thermo Fisher Scien-
tific, Kamstrupvej, Denmark) containing wash medium
GM501 (GM 501 Wash, Gynemed Lensahn, Germany)
under oil. Spermatozoa for the IVF/ICSI procedure were
prepared using standard density gradient procedures
(Isolate, Irvine Scientific, USA) or, in cases with very low
sperm quality, diluted and centrifuged twice at 300 g for
10 min. Standard IVF/ICSI procedures were performed
2–6 h after oocyte retrieval. In the IVF procedure, oocytes
were inseminated with 10,000 progressively motile sper-
matozoa per oocyte. In the ICSI procedure, the cumu-
lus and corona cells were removed with hyaluronidase
(conc.80 IU/m, Gynemed, Lensahn, Germany). The
oocytes were injected with single sperm in a 20 μl droplet
of medium. The injected oocytes were cultured indivi-
dually in 20 μl culture medium (GM 501 Culture,
Gynemed Lensahn, Germany) droplets under oil. On Day
1 (16–20 h after insemination/injection) fertilization was
evaluated.
Peptide extraction
Follicular fluid samples (500 μl) were transferred to
extraction tubes (2 ml) and mixed with an equal amount
of lysis buffer containing 30 mM Tris (SIGMA, St.
Louis, USA), 8 M urea (Acros Organics, New Jersey,
USA), 5 mM Dithiothreitol DTT, Applichem, Darmstadt,
Germany). They were vortexed thoroughly and centri-
fuged at 13,000 rpm for 10 min at room temperature.
The supernatant was then transferred to a 3 K Da filter
Microcon YM-30 filters (Millipore, Billerica, MA, USA),
the filter devices were subsequently centrifuged at
14,000 g for 30 min and the flow through was collected.
Iodoacetamide (IAA, SIGMA, St. Louis, USA) was added
to a final concentration of 0.015 M and the samples
were incubated for 30 min at room temperature in dark.
Then trifluoroacetic acid (TFA) was added to a final
concentration of 0.1%. The mixture was cleaned via solid
phase extraction (SPE) using Pepclean C18 spin column
(Thermo Scientific) according to the manufactuer’s in-
structions and eluted in a final volume of 40 μL. Subse-
quently, the samples were dried in a vacuum
operator. The dried sample was kept at −20°C until
analysis. The peptides were dissolved in 10 μl of 0.1% for-
mic acid (FA) and 5% acetonitrile (ACN).
MS Data Processing
Five microliters from each sample were injected and
separated on an Ultimate® 3000 RSLCnano system
(Dionex, Thermo Scientific, Netherlands) equipped with a
Table 1 Characteristics and treatments of the training and
validation cohorts
Training Validation
Characteristics (n = 34) (n = 32)
ICSI unfertilized mature oocytes(n) 11 7
ICSI fertilized oocytes (n) 10 7
IVF unfertilized mature oocytes(n) 8 9
IVF fertilized oocytes (n) 5 9
Table 2 Patients’ characteristics
fertilized non-fertilized
number of patients 31 35
maternal age 31.2 ± 2.7 31.7 ± 3.7
retrieved oocytes 10.6 ± 4.7 11.0 ± 4.3
matured oocytes 9.2 ± 3.6 9.6 ± 3.3
fertilized oocytes 6.2 ± 3.1 6.4 ± 2.8
IVF 14 17
ICSI 17 18
male factor 16 15
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Thermo Scientific™ Acclaim™ PepMap™ RSLC Nano-Trap
Column with nanoViper™ Fittings, 3 μm Particle Size. The
samples were separated using a buffer A (water/0.1% FA)
and buffer B (water 20%/ACN 80%/FA 0.08%) and a
Thermo Scientific™ EASY-Spray™ column PepMap™ RSLC,
C18, 2 μm, 100 Å, 50 μm x 150 mm using a gradient
of 4 to 10% B in 12 min followed by a gradient of 10
to 35% B in 20 min, a gradient 35 to 65% B in 5 min and
then a final elution and re-equilibration step at 95 and 5%
buffer B respectively for 9 min. The flow-rate was set at
0.300 μL/min. The hybrid quadrupole orbitrap mass spec-
trometer, Q Exactive (Thermo Scientific), was operated in
positive ion mode with a nanospray voltage of 1.5 kV and
a source temperature of 250°C. ProteoMass LTQ/FT-Hy-
brid ESI Pos. Mode CalMix (MSCAL5-1EA SUPELCO,
Sigma-Aldrich) was used as an external calibrant and
the lock mass 445.12003 as an internal calibrant. The
instrument was operated in data-dependent acquisition
(DDA) mode with a survey MS scan at a resolution of
70,000 for the mass range of m/z 400–1600 for precursor
ions, followed by MS/MS scans of the top 10 most intense
peaks with +2, +3, +4 and +5 charged ions above a
threshold ion count of 16,000 at 17,500 resolution
using normalized collision energy (NCE) of 25 eV
with an isolation window of 3.0 m/z, an apex trigger
5–15 s and a dynamic exclusion of 10 s. All data were ac-
quired with Xcalibur 3.0 software (Thermo Scientific).
The LC-MS data were imported to Progenesis Non-
linear software Progenesis v4.1 (Nonlinear Dynamics,
UK) for alignment and normalization to compare the
different sample runs. The software selected automati-
cally the sample run with the greatest similarity to all
other runs as the reference alignment. The aligned runs
containing all ion peak information from all sample files
was exported as mgf and send to Mascot (version 2.2.06;
database swissprot 15,720 accessions). Mass tolerance
was set to 10 ppm for MS and 20 mmu for MS/MS, and
no cleavage enzyme for protein digestion was chosen.
Search parameters allowed for carbamidomethylation
as fixed modification and oxidation of M as variable
modification. Search results were evaluated by Scaffold™
(released version 4.4.5) combining mascot and X! Tandem.
Only peptides with an expected value of <0.05 are reported.
Statistical analysis
The aligned and normalized peptide data were exported
from Progenesis as csv format. The determination of
candidate peptides in the training datasets was accom-
plished by partial least square discriminative analysis
(PLS-DA) using the NIPALS algorithm of Statistica 8.1
(Statsoft). The analysis of variance (ANOVA) was taken
over from Progenesis. The prediction capability of bio-
marker candidates and blind classifying was evaluated by
principle component analysis (PCA) using the NIPALS
algorithm of Statistica 8.1 (Statsoft).
To evaluate the predictive capability of the biomarker
candidates, receiver operating characteristic (ROC) ana-
lysis was carried out with MATLAB (2014 a).
Probability calculations were performed according
to the binomial distribution. The probability of getting
exactly x successes in n trials is given by the probability
mass function: b(x; n, P) = nCx * Px * (1 - P)n – x.
Results
Training datasets
To avoid over fitting of the PLS-DA model, we firstly
examined 2 training datasets of 17 samples and evalu-
ated the differences at the peptidome level of the indi-
vidual follicular fluid samples. Peptides that met both
standards: (1) p < 0.1 with ANOVA, and (2) top 10% on
variable importance ranking were selected and compared
for each experiment. In the first experiment, 12,998
peptides were detected. 394 peptides met the criteria.
In the second experiment, 11,216 peptides were detected,
of which 7760 peptides were in common with the first
experiment (Fig. 1a), and 504 peptides met the criteria.
Among all the interesting candidate peptides described
above, 53 were common to both training datasets (Fig. 1b).
Results of partial least square discriminate analysis were
shown in Fig. 2. Those peptides are listed in Table 3.
Of the 53 peptides, 9 peptides were upregulated in
the fertilized group and 44 were upregulated in the non-
fertilized group (Table 3). The area under ROC curve
Fig. 1 Venn diagram of peptides between two training experiments.
a detected peptides; b important peptides to fertilization
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(AUC) was 0.97, with the sensitivity of 0.82 and the
specificity of 0.84 (Fig. 3).
External validation
The most reliable way of biomarker discovery is to test
the candidates with a large cohort of samples. From the
perspective of generality, 32 samples from an external
study population were analyzed and we predicted the
oocyte fertilization outcome blindly via principle com-
ponent analysis (PCA). The 53 potential biomarkers
discriminate 24 out of the 32 candidates (Fig. 4). The
chance of discriminating 24/32 cases randomly is 0.25%
according to the binomial distribution. As indicated above,
44/53 markers are negatively correlated to fertilization.
Receiver operation characteristic (ROC) analysis indi-
cates that the 53 peptides panel has a high predictive
ability to differentiate FF samples upon fertilization
outcome, with the AUC value of 0.86, the sensitivity
of 81.3%, and the specificity of 68.8%.
Peptide identification
The identification of non-tryptic peptides is challenging
due to the absence of a known cleavage side and the
absence of a basic amino acid at the C-terminus. In total
7102 unique peptides were identified, belonging to 159
proteins (protein false discovery rate (FDR) 0.06% and
peptide FDR 0.00% (Additional file 2: Table S1 and
Additional file 3: Table S3)). From the 53 peptides panel,
we were able to identify 7 peptides derived from 7 differ-
ent proteins (Table 3). The MS spectrum of the identi-
fied peptides is displayed in Additional file 4: Figure S1.
Subcellular and functional annotation of identified peptides
We checked the subcellular localization of all the pep-
tides identified. We found that 5 proteins were localized
Fig. 2 Screening candidate biomarkers in FF for fertilization in training cohorts. PLS scores show evident clustering between fertilized (blue) and
non-fertilized (orange) samples. Samples were separated well in the first component
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Table 3 Peptides set as biomarkers differentially detected between fertilized group and non-fertilized group
m/z RT Charge Highest mean
condition
max fold change Protein Accession number Peptide sequence
Exp.1 Exp.2
401.22 ± 0.00 28.2 ± 0.11 2* non-fertilized 8.94b 3.07c ALBU_Human P02768 AASQAALGL
402.23 ± 0.00 25.3 ± 0.66 1 non-fertilized 2.16b 2.44c
409.18 ± 0.00 24.8 ± 0.22 1 non-fertilized 2.7a 1.99b
410.17 ± 0.00 36.4 ± 0.26 1 fertilized 3.09a 11.07b
412.34 ± 0.00 44.3 ± 0.02 1* non-fertilized 3.36b 2.78b
414.34 ± 0.01 43.3 ± 2.37 1* non-fertilized 1.93c 2.00c
416.37 ± 0.00 46.0 ± 0.15 1* non-fertilized 2.11c 14.22a
424.29 ± 0.01 46.5 ± 0.15 1* fertilized 4.18b 2.24a
426.32 ± 0.02 48.0 ± 0.77 1 fertilized 1.49c 2.33b
438.36 ± 0.02 52.4 ± 1.14 1 non-fertilized 2.67c 2.76a
439.28 ± 0.00 25.0 ± 0.38 1* non-fertilized 2.88b 215.28b
442.94 ± 0.00 27.2 ± 0.60 3 non-fertilized 21.09b 2.57a
459.72 ± 0.00 22.1 ± 0.30 2* non-fertilized 27.37b 12.84b
475.01 ± 0.00 23.4 ± 0.48 4* non-fertilized 5.63b 1.77b
477.28 ± 0.00 47.6 ± 0.48 1* non-fertilized 25.53a 25.84c
478.62 ± 0.00 41.8 ± 0.00 3* non-fertilized 3.02b 1.18c
480.80 ± 0.00 40.5 ± 0.82 2* fertilized 1.22c 1.30c
490.24 ± 0.02 46.5 ± 0.25 1 fertilized 1.70b 8.68c
494.29 ± 0.02 46.4 ± 0.97 1* non-fertilized 549.84a 2.59b IGBP-5_Human P24593 FVGGAENTAHPRII
496.97 ± 0.00 43.1 ± 0.39 3 fertilized 1.36b 1.40b
500.24 ± 0.00 26.7 ± 0.26 3 non-fertilized 341.3c 2.55c
526.41 ± 0.02 52.1 ± 1.08 1 non-fertilized 3.59b 3.10a
528.28 ± 0.00 34.1 ± 0.11 2* fertilized 3.61b 1.94c CO3_Huamn P01024 IHWESASLL
530.29 ± 0.00 45.8 ± 1.13 1* fertilized 1.87c 6.26c
539.66 ± 0.00 44.7 ± 0.41 6 non-fertilized 2.08b 1.73b
545.33 ± 0.00 44.8 ± 0.26 6 non-fertilized Infinita 2.08b
546.99 ± 0.00 44.7 ± 0.42 6 non-fertilized 1.93b 1.60b
552.30 ± 0.00 28.7 ± 0.11 5 non-fertilized 68.46c 2.24b
552.67 ± 0.00 44.7 ± 0.40 6 non-fertilized 3.05c 1.60c
554.33 ± 0.00 44.7 ± 0.41 6 non-fertilized 2.00c 1.70b
558.40 ± 0.00 51.1 ± 0.31 2 non-fertilized 1795.51a Infinita
570.43 ± 0.02 51.9 ± 1.06 1 non-fertilized 4.31b 3.77c
574.68 ± 0.00 44.8 ± 0.40 6 non-fertilized 4.33b 2.39c
576.35 ± 0.00 44.8 ± 0.41 6 non-fertilized 2.24b 1.94b
577.28 ± 0.00 33.5 ± 0.77 1* non-fertilized 1.42b 2.26b
579.18 ± 0.00 44.8 ± 0.39 6 non-fertilized 2.19b 1.95c
588.43 ± 0.01 45.5 ± 1.66 1 non-fertilized 43.29b 4.46c
594.30 ± 0.00 24.0 ± 0.14 2* fertilized 3.09b 2.90a ITIH1_human P19827 LPDRVTGVDTD
602.42 ± 0.00 51.4 ± 1.02 2 non-fertilized 164.28c Infinita
609.72 ± 0.00 30.0 ± 0.00 5 non-fertilized 10.0b 1.91a
643.33 ± 0.00 29.0 ± 1.59 2* non-fertilized Infinitc 2.59a A2AP_human P08697 MEPLGRQLTSGP
658.49 ± 0.02 51.7 ± 0.99 1 non-fertilized 7.59b 11.57b
702.51 ± 0.02 51.6 ± 1.01 1 non-fertilized 6.36b 12.66c
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at extracellular space. Insulin-like growth factor binding
protein-5 (IGBP-5) is secreted by granulosa cells, four
proteins are predicted to come from the circulation
system. Two proteins were predicted to be localized
in the intracellular region, cytoplasm and membrane.
Discussion
The morphological assessments for human embryo
selection in clinic IVF routine is not fully satisfying.
In the last decades, scientists have been attempting to
improve the embryo selection. As the microenviron-
ment of oocyte in vivo, the protein/peptide content of
human follicular fluid has attracted researchers’ interest.
However, to date, research correlates protein/peptide
profiling to IVF outcome has been done yet. The present
study focused on the peptide profile of follicular fluid
with different fertilization outcomes to screen potential
peptide biomarkers for fertilization. Our results have
shown altered level of certain peptides contributed to
the fertilization outcome. By external validation, we con-
firmed the classification capability of these peptides. We
think that the findings reported identify a pool of pep-
tides from which novel IVF-related biomarkers could
be discovered.
In our study, the concentration of one peptide (m/z =
401.23) was significantly less abundant in the fertilized
group and was identified as a fragment derived from
serum albumin (ALBU_Human) (Table 3). In literature,
albumin as a protein has been positively correlated to
oocyte quality. Junko et al. [34] proposed that the bio-
chemically reduced state of albumin in FF may play an
important role in protecting oocytes from oxidative dam-
age. Our data point towards a negative correlation at the
fragment peptide level and might be related to proteolytic
processing.
Table 3 Peptides set as biomarkers differentially detected between fertilized group and non-fertilized group (Continued)
703.75 ± 0.00 31.1 ± 1.97 5 non-fertilized Infinita 1.79b
727.59 ± 0.00 28.0 ± 0.07 4* non-fertilized 1266.81a 2.03b
740.96 ± 0.00 30.6 ± 0.05 5 non-fertilized 4.35b 1.91a PLST_HUMAN P13797 DGETLEELMKLSPEELLLRWANFHLENSGWQ
755.34 ± 0 12.2 ± 0.36 2 non-fertilized 2.04b 2.16a
761.97 ± 0.00 31.0 ± 0.01 5 non-fertilized 6.85b 2.10a
805.39 ± 0.00 35.8 ± 0.01 1* non-fertilized Infinitc 7.38b
859.44 ± 0.00 29.4 ± 0.04 4 non-fertilized Infinita 2.94a
869.68 ± 0.00 32.7 ± 0.15 4 non-fertilized Infinitb 3.92c
924.74 ± 0.00 38.0 ± 0.41 3* non-fertilized Infinitc 9.77b
953.51 ± 0.00 29.1 ± 0.23 3 non-fertilized 12.72b 3.24c DIAP1_HUMAN O60610 AEPHFLSILQHLLLVRNDYEARPQ
ap < 0.01; bp < 0.05; cp < 0.1
*:significant difference in validation experiment
Fig. 3 ROC curve test of FF peptide biomarker candidates. Blue: ROC curve on training dataset; Red: ROC curve on validation dataset
(p-value =0.13)
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We identified m/z = 494.59 derived from insulin-like
growth factor binding protein-5 (IBP-5_Human) as a
second interesting negative biomarker (Table 3). IGF
binding proteins (IGFBP) inhibit insulin-like growth
factor (IGF) actions. The IGF system plays an impor-
tant role in regulating ovarian follicular development
and steroidogenesis [35] and IGFBP proteolysis is a major
mechanism for regulating IGF bioavailability [36]. The
gene of IGFBP-5 was reported to be highly expressed in
rat primary and secondary follicles while dominant folli-
cles were devoid of IGFBP-5 mRNA [37]. In several other
studies [38–42], dominant follicles were characterized by
decreased levels of low molecular weight IGF-binding
proteins (IGF-2,4, and −5). The high abundance of peptide
derived from IGFBP-5 may reflect the increased level of
IGFBP-5 in preovulatory follicle, which reduces the activity
of growth factors, or by an increased activity of its protease
or both.
We identified m/z = 643.33 derived from Alpha-2-
antiplasmin (A2AP_Human) as a third interesting nega-
tive biomarker (Table 3). Alpha-2-antiplasmin is a serine
protease inhibitor, involved in negative regulation of
plasminogen activation. Bayasula et al. confirmed the
presence of A2AP in human FF [43]. The major targets
of this inhibitor are plasmin. Plasmin activity is believed
to be involved in physiological processes such as ovula-
tion [44], cumulus cell layer expansion [44, 45], oocyte
maturation [44, 46] and fertilization [47, 48]. Hormone-
induced coordinated expression of tissue-type PA (tPA)
produced mainly by granulosa cells in the prevolulatory
follicles is responsible for a controlled and directed
proteolysis leading to the rupture of follicles [45]. The
urokinase-type PA (uPA), activates latent proteinases or
growth factors, playing an essential role in the early
growing follicles during cell proliferation and migration
[49]. In addition, plasmin could active pro-enzymes of the
matrix metalloproteinase, which in turn, may also be
involved in ovarian function and regulate follicular
development [49, 50]. In sheep and rat, intra-follicular
injection of A2AP suppresses ovulation of preovulatory
follicles [51, 52]. Huarte et al. [48] reported that the
addition of plasminogen to mouse IVF medium increased
the yield of fertilized eggs, while the addition of plasmin
inhibitors resulted in a significant decrease. Here, for the
first time, we indicate that the differential status of A2AP
may be associated with immature oocyte developmental
stage and might explain the negative biomarker.
We identified m/z = 528.28 as a peptides derived from
Complement component 3 (CO3_Human) in hFF (Table 3)
to be present at a significantly higher level in fertilized
FF group in our study. CO3 has been specifically located
in ovarian follicular fluid in early 1990s [53], however,
the roles of CO3 and its derivatives in FF are not yet
fully known, and the association between CO3 and repro-
ductive capability remains unclear. Gonzales et al. and
Hashemitabar et al. found significantly higher concentra-
tions of the CO3 complement in the FF of fertilized
oocytes [11, 20]. In porc [54], a derivative of CO3,
iCO3b was identified to positively influence oocyte matu-
ration. Those studies are consistent with our finding
as a positive biomarker. In contrast, a study assessing
the FF of IVF patients showed decreased expression
of complement CO3 in their fertilized group [25].
The major difference of Estes’ study was the inclusion
of the oocyte number as dependent variable. Instead of
predicting the outcome of fertilization, it might predict
the differences between good and poor responders.
Additional studies are needed to establish the actual
influence of the complement cascade on reproductive
aging and IVF outcome.
We identified m/z = 594.29 as derived from Inter-
alpha-trypsin inhibitor heavy chain H1 (ITIH1_Human)
as a positive biomarker (Table 3). Proteins of the inter-
alpha-trypsin inhibitor family have been identified as a
serum factor responsible for the stabilization of the
expanding cumulus mass [55]. These proteins do not
enter the follicle until it responds to an ovulatory stimu-
lus. The luteinizing hormone (LH) surge increases the
permeability of the charge and size-selective blood fol-
licle barrier, allowing these serum glycoproteins to enter
the antral cavities of responding follicles [56, 57]. Once
within the antral cavity, the inter-alpha-trypsin inhibitor
(ITI) covalently crosslinked to hyaluronan (HA), driving
conformational changes and thereby remodeling the
morphology and physicochemical properties of HA-rich
extracellular matrices. This modification is the only nat-
urally occurring covalent modification of HA known to
Fig. 4 Visual identification of the hFF samples using the 53 peptide
biomarker candidates. PCA score plots derived from PCA of 53
important biomarker candidates of 32 hFF with fertilized oocytes or
non-fertilized oocytes. PC1, explaining 36.6% of the variability is
clearly associated to the outcome of fertilization
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date. The interaction was shown to be critical to matrix
stabilization in expansion of the cumulus-oocyte com-
plex (COC) [58, 59]. Huang et al. have shown that HA
interacts strongly with ITIH1 and ITIH2 in vitro, and this
binding was highly resistant to ionic strength and pH [60].
In another vivo study, mice lacking intact IαI family
members fail to form a stable cumulus matrix and the
naked ovulated oocytes are not fertilized in vivo [58].
Conclusion
Despite progress in the treatment of IVF and advances
in novel techniques, selection of embryos based on the
morphologic and morphometric parameters alone is not
fully satisfactory. More accurate selection of oocytes and
embryos should improve success rates after IVF treatment.
Follicle development and oocyte maturation, require or
bring about changes to oocyte microenvironment. Given
the complexity of the numerous independent processes
involved in oocyte development, it is unlikely that a single
biomarker can predict the result of in vitro fertilization. By
characterization of the FF peptidome, we present a profile
of biomarkers associated with fertilization outcome. This
may offer prognostic information aiding the selection of
the most viable oocytes and hence embryos. The current
results confirmed our hypothesis that peptide profiling
is a promising approach to screen biomarkers for
fertilization potential. Comparison of our results with
proteomic studies of hFF indicates that the different
analytical tools each bring their own selectivity.
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